[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"doc-seo-355362-105":3,"detail-sidebar-cat-0-en-105":81,"doc-detail-355362-en":131},{"code":4,"msg":5,"data":6},0,"ok",{"site_id":7,"language":8,"slug":9,"title":10,"keywords":11,"description":12,"schema_data":13,"social_meta":74,"head_meta":76,"extra_data":78,"updated_unix":80},105,"en","the-effect-of-her3-expression-on-prognosis-in-egfr-mutant-non-small-cell-lung-cancer-a-retrospective-real-world-study","The Effect of HER3 Expression on Prognosis in EGFR-Mutant Non-Small Cell Lung Cancer - A Retrospective Real-World Study","","Non-small cell lung cancer (NSCLC) remains a leading cause of cancer-related mortality, and EGFR-targeted tyrosine kinase inhibitors (TKIs) improve outcomes in EGFR-mutant disease but resistance limits long-term efficacy. HER3 has been linked to TKI resistance via EGFR/HER2 heterodimerization and PI3K/AKT signaling, yet its real-world prognostic and predictive role is incompletely defined. This retrospective single-center study assessed HER3 by immunohistochemistry in 52 EGFR-mutant NSCLC patients receiving TKI-based therapy.",{"@graph":14,"@context":73},[15,34,56],{"@type":16,"itemListElement":17},"BreadcrumbList",[18,23,27,31],{"item":19,"name":20,"@type":21,"position":22},"https://docshare.wps.com","Home","ListItem",1,{"item":24,"name":25,"@type":21,"position":26},"https://docshare.wps.com/document/","Document",2,{"item":28,"name":29,"@type":21,"position":30},"https://docshare.wps.com/document/research-report/","Research & Report",3,{"item":32,"name":10,"@type":21,"position":33},"https://docshare.wps.com/document/the-effect-of-her3-expression-on-prognosis-in-egfr-mutant-non-small-cell-lung-cancer-a-retrospective-real-world-study/355362/",4,{"url":32,"name":10,"@type":35,"image":36,"author":41,"headline":10,"publisher":44,"fileFormat":47,"inLanguage":8,"description":12,"dateModified":48,"datePublished":49,"encodingFormat":47,"isAccessibleForFree":50,"interactionStatistic":51},"DigitalDocument",{"url":37,"@type":38,"width":39,"height":40},"https://docshare.wps.com/thumbnails/the-effect-of-her3-expression-on-prognosis-in-egfr-mutant-non-small-cell-lung-cancer-a-retrospective-real-world-study/355362.png","ImageObject",300,407,{"name":42,"@type":43},"Jake","Person",{"url":19,"name":45,"@type":46},"DocShare","Organization","application/pdf","2026-10-29","2026-09-22",true,{"@type":52,"interactionType":53,"userInteractionCount":55},"InteractionCounter",{"@type":54},"ViewAction",11,{"@type":57,"mainEntity":58},"FAQPage",[59,65,69],{"name":60,"@type":61,"acceptedAnswer":62},"What clinical question does the study address regarding HER3 in EGFR-mutant NSCLC?","Question",{"text":63,"@type":64},"It evaluates whether HER3 expression is associated with prognosis and with sensitivity to EGFR-TKI treatment in EGFR-mutant NSCLC, using real-world clinical cohorts.","Answer",{"name":66,"@type":61,"acceptedAnswer":67},"How was HER3 expression measured in the study?",{"text":68,"@type":64},"HER3 protein expression was determined by immunohistochemistry (IHC) on formalin-fixed, paraffin-embedded tumor tissue using a specified anti-HER3 antibody.",{"name":70,"@type":61,"acceptedAnswer":71},"What overall pattern did the study find between HER3 status and outcomes?",{"text":72,"@type":64},"HER3 expression was associated with reduced first-line TKI efficacy, while sequencing chemotherapy before TKI appeared to attenuate the impact of HER3 positivity; however, statistical significance was not reached.","https://schema.org",{"og:url":32,"og:type":75,"og:title":10,"og:site_name":45,"og:description":12},"article",{"robots":77,"canonical":32},"index,follow",{"doc_id":79,"site_id":7},355362,1790175601,{"code":4,"msg":82,"data":83},"success",[84,88,92,96,101,106,111,115,120,123,127],{"id":22,"doc_module":4,"doc_module_name":25,"category_name":85,"show_sort_weight":86,"slug":87},"Story & Novel",90,"story-novel",{"id":26,"doc_module":4,"doc_module_name":25,"category_name":89,"show_sort_weight":90,"slug":91},"Literature",80,"literature",{"id":33,"doc_module":4,"doc_module_name":25,"category_name":93,"show_sort_weight":94,"slug":95},"Exam",70,"exam",{"id":97,"doc_module":4,"doc_module_name":25,"category_name":98,"show_sort_weight":99,"slug":100},5,"Comic",60,"comic",{"id":102,"doc_module":4,"doc_module_name":25,"category_name":103,"show_sort_weight":104,"slug":105},6,"Technology",50,"technology",{"id":107,"doc_module":4,"doc_module_name":25,"category_name":108,"show_sort_weight":109,"slug":110},7,"Healthcare",40,"healthcare",{"id":112,"doc_module":4,"doc_module_name":25,"category_name":29,"show_sort_weight":113,"slug":114},8,30,"research-report",{"id":116,"doc_module":4,"doc_module_name":25,"category_name":117,"show_sort_weight":118,"slug":119},9,"Religion & Spirituality",20,"religion-spirituality",{"id":118,"doc_module":4,"doc_module_name":25,"category_name":121,"show_sort_weight":118,"slug":122},"World Cup","world-cup",{"id":124,"doc_module":4,"doc_module_name":25,"category_name":125,"show_sort_weight":124,"slug":126},10,"Lifestyle","lifestyle",{"id":128,"doc_module":4,"doc_module_name":25,"category_name":129,"show_sort_weight":97,"slug":130},19,"General","general",{"code":4,"msg":82,"data":132},{"doc_id":79,"user_id":133,"nickname":42,"user_avatar":134,"doc_module":4,"category_id":112,"category_name":29,"doc_title":10,"doc_description":12,"doc_content":135,"file_id":136,"file_url":137,"file_type":138,"file_size":139,"view_count":55,"is_deleted":4,"is_public":22,"is_downloadable":22,"audit_status":22,"page_count":140,"language":141,"language_code":8,"site_id":7,"html_lang":8,"table_of_contents":142,"faqs":143,"seo_title":144,"seo_description":12,"update_tm":145,"read_time":146,"preview_page_count":33,"preview_urls":147},962084928904,"https://ap-avatar.wpscdn.com/davatar_155a257f0dc6eb9ab79c44ca47cae57d","Article  \nThe Effect of HER3 Expression on Prognosis in EGFR-Mutant Non-Small Cell Lung Cancer: A Retrospective Real-World Study  \nCanan Yıldız 1, *, Meltem Baykara 1, Hacer Demir 1, Ramazan Cosar 1, Sedat Yıldız 1, Beyza Unlu 1, Ya¸sar Culha 1, Duygu Ozaskin 1, Merve Kuday Özkan 1, Fariz Emrah Özkan 1 and Çi ˘gdem Özdemir 2  \nAcademic Editor: Hisao Imai  \nReceived: 22 February 2026  \nRevised: 7 March 2026  \nAccepted: 10 March 2026  \nPublished: 13 March 2026  \nCopyright: © 2026 by the authors. Published by MDPI on behalf of the Lithuanian University of Health Sciences. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license.  \n1 Department of Medical Oncology, Afyonkarahisar Health Sciences University, Afyonkarahisar 03030, Turkey; [meltembaykara@yahoo.com](meltembaykara@yahoo.com) (M.B.); [drhacerdemir@gmail.com](drhacerdemir@gmail.com) (H.D.); [ramazancosar@gmail.com](ramazancosar@gmail.com) (R.C.); [drsedatyildiz06@gmail.com](drsedatyildiz06@gmail.com) (S.Y.); [dr-beyza@hotmail.com](dr-beyza@hotmail.com) (B.U.); [drjasar@hotmail.com](drjasar@hotmail.com) (Y.C.); [dygalan91@gmail.com](dygalan91@gmail.com) (D.O.); [mervekuday@gmail.com](mervekuday@gmail.com) (M.K.Ö.); [dr.emrah.oz@gmail.com](dr.emrah.oz@gmail.com) (F.E.Ö.)  \n2 Department of Medical Pathology, Afyonkarahisar Health Sciences University, Afyonkarahisar 03030, Turkey; [drcozdemir75@hotmail.com](drcozdemir75@hotmail.com)  \n* Correspondence: [drcanansarikayayildiz@gmail.com](drcanansarikayayildiz@gmail.com)  \nAbstract  \nBackground and Objectives: Non-small cell lung cancer (NSCLC) accounts for approximately 85% of all lung cancers and remains a leading cause of cancer-related mortality worldwide. EGFR-targeted tyrosine kinase inhibitors (TKIs) have substantially improved outcomesin EGFR-mutant NSCLC; however, primary and acquired resistance continues to limit their long-term efficacy. HER3 (receptor tyrosine-protein kinase ErbB3), a member of the ErbB receptor family, has been implicated in TKI resistance through heterodimerization with EGFR and HER2, leading to downstream PI3K/AKT pathway activation. Despite its biological plausibility as a resistance mediator, the clinical significance of HER3 expression as a prognostic and predictive biomarker in EGFR-mutant NSCLC has not been thoroughly characterized in real-world cohorts. Materials and Methods: This retrospective, single-center study included 52 patients diagnosed with EGFR-mutant NSCLC who received TKI therapy at Afyonkarahisar Health Sciences University between January 2011 and September 2023 . HER3 protein expression was evaluated by immunohistochemistry (IHC) on formalinfixed, paraffin-embedded tumor tissue sections using the Huabio anti-HER3 antibody (clone PD00-44, 1:2000 dilution) . Staining in more than 30% of tumor cells was considered HER3-positive; membranous staining intensity was scored on a 1–3 scale. Progression-free survival (PFS1, PFS2) and overall survival (OS) were analyzed using the Kaplan–Meier method and log-rank test. Statistical significance was set at p \u003C 0.05 . Results: Of 52 patients (55.8% female; mean age 64.5 years), 59.6% received chemotherapy and 40.4% received an EGFR TKI as first-line treatment; erlotinib constituted 71.2% of targeted therapies. In the first-line TKI group, HER3-negative patients had a numerically longer median PFS1 compared with HER3-positive patients (14.0 vs. 7.1 months; p = 0.285); however, this difference did not reach statistical significance and should be interpreted with caution given the small sample size. In contrast, among patients receiving first-line chemotherapy, HER3 staining status did not meaningfully affect PFS1 (4.1 vs. 2.5 months; p = 0.063) . In second-line treatment, HER3-positive patients who received TKI after prior chemotherapy demonstrated a PFS2 comparable to or slightly exceeding that of HER3-negative patients (21.8 vs. 1","cbCaibGV28iQmeuM","https://ap.wps.com/l/cbCaibGV28iQmeuM","pdf",1098167,14,"English","# Abstract\n# Introduction\n# Materials and Methods\n# Results\n# Conclusions","[{\"question\":\"What clinical question does the study address regarding HER3 in EGFR-mutant NSCLC?\",\"answer\":\"It evaluates whether HER3 expression is associated with prognosis and with sensitivity to EGFR-TKI treatment in EGFR-mutant NSCLC, using real-world clinical cohorts.\"},{\"question\":\"How was HER3 expression measured in the study?\",\"answer\":\"HER3 protein expression was determined by immunohistochemistry (IHC) on formalin-fixed, paraffin-embedded tumor tissue using a specified anti-HER3 antibody.\"},{\"question\":\"What overall pattern did the study find between HER3 status and outcomes?\",\"answer\":\"HER3 expression was associated with reduced first-line TKI efficacy, while sequencing chemotherapy before TKI appeared to attenuate the impact of HER3 positivity; however, statistical significance was not reached.\"}]","The Effect of HER3 Expression on Prognosis in EGFR-Mutant Non-Small Cell Lung Cancer - A Retrospective Real-World Study | PDF",1790118071,35,[148,152,156,160],{"page_no":22,"url":149,"width":150,"height":151},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/1d9666cc4206c4323b6a7ee4715bf919.webp",983,1390,{"page_no":26,"url":153,"width":154,"height":155},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/1cf4c59975b4a8d1d22af3dc01fa500a.webp",982,1388,{"page_no":30,"url":157,"width":158,"height":159},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/35a742d0a80041071a264d858a5b069c.webp",981,1387,{"page_no":33,"url":161,"width":162,"height":163},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/8324a1cc856790979f83a45e69913a9f.webp",980,1385]